04/16/2026 | Press release | Archived content
France-Based Biotechnology Leader Positions Capital Region for Cutting-Edge Industry Job Growth
Project Further Advances New York State's Role as Global Leader in Life Science Ecosystem
Governor Kathy Hochul today announced that France-based One Biosciences has chosen Albany as its first United States location. The company plans to staff and equip a high-complexity laboratory and computational analytics operation on New Scotland Avenue, capable of advancing next-generation cancer diagnostics and therapeutic decision-support. Empire State Development is supporting this expansion with up to $525,000 in performance-based Excelsior Jobs Program tax credits in exchange for the company's job commitments, which anticipate 42 life science jobs and $18 million in investments over the next five years.
"Life science research and development is vital to creating the treatments that help people heal, survive and live longer," Governor Hochul said. "Through our targeted efforts, we are working to ensure that cutting edge companies like One Biosciences not only grow here, but that the next generation of medical breakthroughs happen in New York State."
One Biosciences, based in Paris, France, will bring its proprietary technology to this first-of-its-kind hub in Albany to address the unmet clinical and scientific needs to characterize the tumor ecosystem. The company is developing technology to better understand each patient's cancer, helping doctors around the world to match patients to the therapies most likely to help them.
Empire State Development President, CEO and Commissioner Hope Knight said, "Under Governor Hochul's leadership, New York's strategic investments to grow the life science ecosystem throughout the state continue to bear fruit and generate dividends. One Biosciences' decision to establish its first U.S. footprint in Albany is a testament to the strength of the industry here, and the opportunities available for life science companies looking to expand and thrive."